


RealRate

PHARMACEUTICAL 2020

Vanda Pharmaceuticals Inc. Rank 9 of 362









PHARMACEUTICAL 2020



Vanda Pharmaceuticals Inc. Rank 9 of 362



The relative strengths and weaknesses of Vanda Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vanda Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 454% points. The greatest weakness of Vanda Pharmaceuticals Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 56% points.

The company's Economic Capital Ratio, given in the ranking table, is 331%, being 634% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	354,136
Cost of Goods Sold	0
Intangible Assets	23,037
Liabilities, Current	59,505
Liabilities, Non-Current	13,298
Other Assets	102,711
Other Compr. Net Income	248
Other Expenses	-60,532
Other Liabilities	0
Other Net Income	0
Property and Equipment	3,864
Research and Development	48,649
Revenues	233,406
Selling, General and Administrative Expense	129,736

Output Variable	Value in 1000 USD
Assets	483,748
Liabilities	72,803
Expenses	117,853
Stockholders Equity	410,945
Net Income	115,553
Comprehensive Net Income	115,677
Economic Capital Ratio	331%

